Intellia (NTLA) CEO John M. Leonard Sells Shares

What Happened
John M. Leonard, President, CEO and Director of Intellia Therapeutics (NTLA), sold a total of 22,675 shares in open-market transactions: 19,890 shares on 2026-08-20 at a weighted average price of $12.60 (proceeds $250,614) and 2,785 shares on 2026-08-21 at $13.00 (proceeds $36,205). These were sales (routine disposition) rather than purchases.

Key Details

• Transaction dates and amounts:
  • 2026-08-20: 19,890 shares sold, weighted average price $12.60, proceeds $250,614. (Shares sold across prices $12.32–$13.00 per footnote.)
  • 2026-08-21: 2,785 shares sold at $13.00, proceeds $36,205.
• Total shares sold: 22,675; total reported proceeds: ~$286,819.
• Filing: Form 4 filed 2026-08-24; filing appears timely given the transaction dates.
• Footnotes:
  • Sales were automatic under a Rule 10b5-1 trading plan adopted May 21, 2026.
  • The $12.60 price is a weighted average; per-price breakdown for Aug 20 sales can be provided on request.
  • Some shares are held by the John M. Leonard 2015 Irrevocable Trust.
• Shares owned after the transactions: not specified in the provided filing excerpt.

Context
These were disposition transactions executed under a pre-established 10b5-1 plan, which typically indicate pre-planned, automatic sales rather than discretionary trades. The filing shows routine insider selling; it does not by itself indicate the insider’s view on company fundamentals.